tegituridine

Tegituridine (HS-10388) is a novel small-molecule mu-opioid receptor (MOR) agonist developed by Hansoh Pharmaceutical for the treatment of postoperative pain. It is characterized as a G-protein biased agonist, designed to selectively activate the G-protein signaling pathway while minimizing the recruitment of beta-arrestin-2, a protein associated with opioid-induced side effects such as respiratory depression and gastrointestinal dysfunction. By favoring analgesic signaling over pathways that lead to adverse events, tegituridine aims to provide a safer alternative to traditional opioids like sufentanil. Clinical development, including Phase 3 trials, has focused on its efficacy in postoperative pain management and its impact on psychomotor recovery, particularly in vulnerable populations such as frail elderly patients undergoing laparoscopic surgery.

Brand names

特吉妥定

Other names

tegituridinetegitidine